Original reporting and analysis on the stories shaping biotech.
Sarepta's $3 million gene therapy for Duchenne muscular dystrophy has killed children from liver failure. Now the company is betting on an enhanced immunosuppression regimen to fix its flagship product, with implications for the entire gene therapy field.
AbbVie paid up to $1.2 billion for Gilgamesh's lead psychedelic depression drug. The team kept everything else, spun out a new company, and just raised $60 million to build what could be an oral alternative to ketamine.
A Minneapolis startup just raised $50 million to test whether zapping your gut lining with electricity can treat type 2 diabetes. It sounds wild, but Mayo Clinic helped build it, Intuitive Ventures is backing it, and the FDA gave it a fast track.
Innate Pharma just walked away from the NK cell engager technology it spent two decades building. With cash running out by Q3 2026 and its ANKET platform reduced to a single preclinical asset, the Marseille biotech is betting everything on three surviving programs.
Insmed's inhaled antibiotic ARIKAYCE just cleared a major hurdle that could transform it from a last-resort drug into a first-line treatment for a rare lung infection most people have never heard of. The commercial and clinical stakes are bigger than you'd think.
Maze Therapeutics dropped Phase 2 kidney disease data and called it potentially best-in-class. The stock promptly cratered. A look at what the numbers actually showed, and why the market wasn't buying what Maze was selling.
Merck is paying $6.7 billion for Terns Pharmaceuticals and its early-stage leukemia drug. With Keytruda's $29.5 billion in annual sales about to face patent expiration, this is what urgency looks like in pharma.
For nearly 20 years, kids with Hunter syndrome had a treatment that couldn't reach their brains. Denali Therapeutics just got FDA approval for Avlayah, the first enzyme therapy that crosses the blood-brain barrier, and it could change the game for rare neurological diseases.
A UK biotech with a Nobel laureate co-founder just emerged from seven years of stealth mode with $87 million and a plan to do what no approved drug can: remove the protein clumps already destroying patients' hearts. The investor syndicate behind the bet is stacked.
The FDA just flagged a seizure risk hiding inside the most common Parkinson's drug in America. The culprit? A slow vitamin drain that nobody was checking for. Two patients have already died, but the fix might cost less than your morning coffee.
Sarepta just dropped the first human data from its blockbuster $11 billion siRNA partnership with Arrowhead, and the results suggest their gene-silencing drugs can actually reach muscle tissue safely. For two rare diseases with zero approved treatments, that's a very big deal.
Genmab dropped $1.8 billion on ProfoundBio's cancer drug pipeline in 2024. Less than two years later, two of the three clinical-stage assets are dead and a third is barely enrolling patients. Now the entire deal rides on one surviving drug.
Gilead just dropped $2.175 billion on a startup barely old enough to walk, betting that cancer-fighting T-cell engagers can reset the immune system for autoimmune diseases. The kicker? No clinical trial results have been published yet.
Merck is dropping $6.7 billion on Terns Pharmaceuticals and its single Phase 1/2 cancer drug. With Keytruda's patent cliff looming in 2028, the pharma giant is making one of the most aggressive early-stage bets in recent memory.
Merck just handed $20 million to a three-year-old startup that reads your cells' natural mutations like a drug discovery cheat code. The deal could be worth $2.2 billion if Quotient Therapeutics can crack new targets for inflammatory bowel disease.
GlycoNex and Nippon Kayaku just partnered on a cancer drug that plays dead in your bloodstream and only activates inside tumors. In the middle of an ADC gold rush worth tens of billions, this "Antibody Lock" technology could be the stealth upgrade the field needs.
Innovent Biologics just matched Regeneron's $11B blockbuster Eylea in a 600-patient Phase 3 trial for wet AMD, but the real story is what happened next: better dosing durability, a cleaner safety signal, and a shot at China's fast-growing retinal disease market.
Iranian strikes knocked out a third of the world's helium supply, and 50,000 MRI scanners are about to feel it. The crisis linking party balloons to cancer screenings is more urgent than you think.
Aardvark Therapeutics just froze its entire obesity pipeline after cardiac safety signals emerged, sending shares plummeting 54%. The company's clever approach to weight loss (tricking gut bitter taste receptors into suppressing hunger) may have a fatal flaw: those same receptors exist in the heart.
A startup just emerged from stealth with $42 million and early clinical data showing it can grow new brain cells from a patient's own blood, then implant them to restore movement in Parkinson's patients. The results from five patients are turning heads.
Rocket Pharmaceuticals is getting a second shot at FDA approval for Kresladi, a gene therapy that achieved 100% survival in kids with a disease that kills most of them before age two. The first rejection wasn't about science; it was about manufacturing. March 28 is decision day.
Abbott just closed its $23 billion acquisition of Exact Sciences, the company behind Cologuard, reshaping the cancer screening landscape overnight. The deal pairs Abbott's global distribution muscle with the most dominant non-invasive cancer testing franchise in the country, and the pipeline goes way beyond poop tests.
Join thousands of biotech professionals who start their day with our free, daily briefing.